Efficacy and safety of neuroprotection in patients with primary open-angle glaucoma
Authors:
- 1 January 2019
- journal article
- research article
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 135 (2) , 83-92
Abstract
Elevated intraocular pressure (IOP) is considered one of the main factors in the development and progression of primary open-angle glaucoma (POAG). The main schemes of drug treatment and cell protection from glaucomatous damage are aimed particularly at reducing IOP. However, it is possible for the disease to progress with normalized IOP. This determines the need to search for drugs that would affect other pathogenetic links of the progression of POAG. To study the effect of 'Cytoflavin' drug on the stabilization of glaucomatous optic neuropathy in patients with POAG. The study included 103 patients with initial or developed POAG. Patients were randomized into two groups using random numbers: the control group patients (n=50) receiving standard conservative treatment, and the main group (n=53), where patients received the combined drug with metabolic action 'Cytoflavin'. In addition to standard ophthalmological studies, all patients underwent biological, electrophysiological, perimetric, structural topographic, laboratory and sociological examinations before and after the treatment. By the end of the 3rd month of the treatment, the patients of the main group showed positive dynamics of the amplitude and phase characteristics of bioelectric activity of the retina, improvement in the total sensitivity of the retina for central field of view. Cytoflavin contributed to reducing the rate of progression of glaucoma according to optical coherence tomography: stabilization of the thickness of the nerve fiber layer, reduction of the rate of global and focal loss of retinal ganglion cells. In patients of the main group, by the end of the 3rd month, the severity of oxidative stress has significantly reduced and the antioxidant defense improved. On the background of stabilized glaucomatous process, a subjective improvement in general and psycho-emotional health, increased confidence in the success of the therapy and thus the improved the quality of life was observed in comorbid patients of the main group. Cytoflavin acts on the mechanisms that enhance the protection of the retina against the effects of reperfusion injury and oxidative stress, contributes to the metabolic adaptation of neurons and leads to a more favorable variant of POAG.Keywords
This publication has 13 references indexed in Scilit:
- Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucomaExpert Opinion on Investigational Drugs, 2016
- Translating the Low Translaminar Cribrosa Pressure Gradient Hypothesis into the Clinical Care of GlaucomaSeminars in Ophthalmology, 2016
- Causes of vision loss worldwide, 1990–2010: a systematic analysisThe Lancet Global Health, 2013
- The vast complexity of primary open angle glaucoma: Disease genes, risks, molecular mechanisms and pathobiologyProgress in Retinal and Eye Research, 2013
- Mitochondria: Their role in ganglion cell death and survival in primary open angle glaucomaExperimental Eye Research, 2010
- Dysfunctional regulation of ocular blood flow: A risk factor for glaucoma?Clinical Ophthalmology, 2008
- Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma2008
- The impact of ocular blood flow in glaucomaProgress in Retinal and Eye Research, 2002
- Delayed Functional Loss in Glaucoma LII Edward Jackson Memorial LectureAmerican Journal of Ophthalmology, 1996
- Does Reduction of Intraocular Pressure (IOP) Prevent Visual Field Loss in Glaucoma?Optometry and Vision Science, 1983